Intellia Therapeutics, Inc. (NTLA)

Market Cap	885.64M
Revenue (ttm)	45.57M
Net Income (ttm)	-525.91M
Shares Out	103.58M
EPS (ttm)	-5.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,825,317
Open	8.45
Previous Close	8.12
Day's Range	8.43 - 8.89
52-Week Range	5.90 - 28.18
Beta	2.33
Analysts	Buy
Price Target	38.60 (+351.46%)
Earnings Date	May 8, 2025

About NTLA

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2016
• Employees: 403
• Stock Exchange: NASDAQ
• Ticker Symbol: NTLA
• Website: https://www.intelliatx.com

Financial Performance

In 2024, Intellia Therapeutics's revenue was $57.88 million, an increase of 59.55% compared to the previous year's $36.28 million. Losses were -$519.02 million, 7.86% more than in 2023.

Analyst Forecast

According to 20 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $38.6, which is an increase of 351.46% from the latest price.

Price Target

$38.6

(351.46% upside)

Analyst Consensus: Buy